Promising stomach cancer combo trial pulled before it even started
NCT ID NCT06967987
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if adding a targeted drug (bemarituzumab) to standard chemotherapy (FLOT) could improve outcomes for people with a certain type of stomach or gastroesophageal junction cancer that overexpresses FGFR2b. The treatment was given before and after surgery. However, the trial was withdrawn before enrolling any participants, so no results are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC AND GASTRO-OESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHRU de Brest
Brest, 29609, France
-
CHU de Poitiers
Poitiers, 86021, France
-
CHU de Rennes
Rennes, 35000, France
-
Centre François Baclesse
Caen, 14076, France
-
Centre Georges François Leclerc
Dijon, 21079, France
-
Centre Léon Bérard
Lyon, 69373, France
-
Gustave Roussy
Villejuif, 94805, France
-
Institut Bergonié
Bordeaux, 33000, France
-
Institut Paoli Calmette
Marseille, 13273, France
-
Institut de Cancérologie de Lorraine
Vandœuvre-lès-Nancy, 54519, France
-
Institut de Cancérologie de l'Ouest
Angers, 49055, France
-
Institut de Cancérologie de l'Ouest
Saint-Herblain, 44805, France